| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
32 |
| Employees |
888 |
| Revenues (TTM) (Millions $) |
559 |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
244 |
| Capital Exp. (TTM) (Millions $) |
50 |
Business Description
GW Pharmaceuticals Plc is a British biopharmaceutical company that is focused on developing medicines derived from cannabis. The company was founded in 1998 and has its headquarters in Cambridge, United Kingdom. It is listed on the NASDAQ stock exchange under the ticker symbol "GWPH".
GW Pharmaceuticals has been a pioneer in the development of cannabis-based medicines. The company's primary focus is on the development and commercialization of medicines for the treatment of epilepsy, multiple sclerosis, and cancer pain. Its lead product, Epidiolex, is the first FDA-approved cannabis-based drug for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
GW Pharmaceuticals has also developed Sativex, a cannabis-based medicine for the treatment of spasticity in multiple sclerosis patients. Sativex is currently approved for use in over 25 countries, including the United Kingdom, Spain, Germany, Canada, and Australia.
The company has a strong research and development program, with a focus on developing medicines that have the potential to treat a wide range of medical conditions. GW Pharmaceuticals has a team of over 600 employees, including scientists, doctors, and other medical professionals, who are dedicated to developing innovative medicines.
In addition to its pharmaceutical activities, GW Pharmaceuticals also has a program focused on the development of plant-based therapies for the treatment of skin diseases such as eczema, psoriasis, and acne. The company has also developed a range of CBD-based products, including skin care products and drinks.
GW Pharmaceuticals has a diverse and robust pipeline of products in various stages of development, including additional cannabis-based medicines for the treatment of other conditions. The company is committed to the highest standards of scientific rigor and is focused on providing safe and effective treatments for patients with unmet medical needs.
Company Address: Sovereign House Cambridge 0
Company Phone Number: 1223 266800 Stock Exchange / Ticker: NASDAQ GWPH
|
%
0.19% 